Results 101 to 110 of about 27,150 (219)

Blau Syndrome (Juvenile Systemic Granulomatosis): State‐Of‐The‐Art Review

open access: yesPediatric Dermatology, EarlyView.
ABSTRACT Blau syndrome (BlauS) is a rare pediatric autoinflammatory disorder due to NOD2 gain‐of‐function pathogenic variants characterized by a triad of granulomatous dermatitis, arthritis, and uveitis, which can progress to systemic complications if untreated.
Ou Jia (Emilie) Wang   +3 more
wiley   +1 more source

Hepatotoxicity due to tocilizumab and anakinra in rheumatoid arthritis: two case reports

open access: yesInternational Journal of General Medicine, 2011
Mahmud Mahamid1,3, Kalman Paz3, Rifaat Safadi1,21Liver Unit, Holy Family Hospital, Nazareth, Israel; 2Hadassah Medical Center, 3Shaare Zedek Medical Center, Jerusalem, IsraelAbstract: Elevation of liver enzymes in patients with rheumatoid arthritis ...
Mahamid M, Paz K, Safadi R
doaj  

Intravenous Anakinra for Macrophage Activation Syndrome May Hold Lessons for Treatment of Cytokine Storm in the Setting of Coronavirus Disease 2019

open access: yesACR Open Rheumatology, 2020
Macrophage activation syndrome (MAS) and hemophagocytic lymphohistiocytosis (HLH) are increasingly recognized as being on a continuum of cytokine storm syndromes, with different initiating pathways culminating in cytotoxic dysfunction and uncontrolled ...
Theresa L. Wampler Muskardin
doaj   +1 more source

Defining the optimal biological monotherapy in rheumatoid arthritis: a systematic review and meta-analysis of randomised trials [PDF]

open access: yes, 2016
Objectives To summarize and compare the benefits and harms of biological agents used as monotherapy for rheumatoid arthritis (RA) in order to inform decisions for patients who are intolerant to conventional DMARD therapy.
Bliddal, Henning   +12 more
core   +2 more sources

Autoimmune Diseases: Molecular Pathogenesis and Therapeutic Targets

open access: yesMedComm, Volume 6, Issue 7, July 2025.
This review provides a comprehensive overview of common autoimmune diseases, details clinical manifestations and summarizes the pathogenesis, including the breakdown of immune tolerance, initiation of autoimmune responses, and their progressive amplification.
Xiaoshuang Song   +9 more
wiley   +1 more source

A Retrospective Patient Chart Review and Survey in Patients with Cryopyrin-associated Periodic Syndromes Treated with Anakinra

open access: yesJournal of Health Economics and Outcomes Research, 2013
**Background:** Cryopyrin-associated periodic syndromes (CAPS) is a group of rare autoinflammatory diseases. Little is known about the burden of disease, patients’ views on treatment, and adverse events (AEs) with current therapy.
Helen J. Lachmann   +5 more
doaj   +1 more source

Role of Interleukin-1 in Radiation-Induced Cardiomyopathy [PDF]

open access: yes, 2015
Thoracic X-ray therapy (XRT), used in cancer treatment, is associated with increased risk of heart failure. XRT-mediated injury to the heart induces an inflammatory response leading to cardiomyopathy.
Abbate, Antonio   +9 more
core   +3 more sources

Specialized Pro‐Resolving Mediators as Emerging Players in Cardioprotection: From Inflammation Resolution to Therapeutic Potential

open access: yesActa Physiologica, Volume 241, Issue 7, July 2025.
ABSTRACT Aim Timely myocardial reperfusion is essential for restoring blood flow to post‐ischemic tissue, thereby reducing cardiac injury and limiting infarct size. However, this process can paradoxically result in additional, irreversible myocardial damage, known as myocardial ischemia–reperfusion injury (MIRI).
Anna De Bartolo   +3 more
wiley   +1 more source

The Use of IL-1 Receptor Antagonist (Anakinra) in Idiopathic Recurrent Pericarditis: A Narrative Review

open access: yesCardiology Research and Practice, 2016
Recurrent pericarditis is a complication of acute pericarditis in 20–30% of the patients and is usually idiopathic in nature. The underlying pathogenesis of this condition remains unclear, although immune-mediated mechanisms seem likely.
Shankar Baskar   +2 more
doaj   +1 more source

Treatment of cytokine storm syndrome with IL‐1 receptor antagonist anakinra in a patient with ARDS caused by COVID‐19 infection: A case report

open access: yesClinical Case Reports, 2020
The biological anakinra appears promising to halt cytokine storm syndrome seen in severe courses of COVID‐19. However, immunosuppression with anakinra may facilitate sepsis, necessitating continuous screening for bacterial superinfections.
Leonard Kaps   +5 more
doaj   +1 more source

Home - About - Disclaimer - Privacy